🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Refractory Metastatic Colorectal Cancer

Sacituzumab Govitecan in Metastatic Colorectal Cancer NCT06243393Phase 2, Phase 31 site📍 Heidelberg University Hospital Heidelberg · Tests: Sacituzumab Govitecan (SG), Physicians Choice (PhC). CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer NCT06530303Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine, Interleukin-2, Pembrolizumab Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases NCT04491929n/a1 site📍 Aarhus N Aarhus University Hospital Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer NCT06992648Phase 31 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Trifluridine/Tipiracil + Regorafenib, Trifluridine/tipiracil + bevacizumab Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer NCT06992258Phase 213 sites📍 New Haven📍 Miami Beach📍 Orlando Criterium, Inc. · Tests: Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib LYL273 for Patients With Relapsed or Refractory mCRC NCT05319314Phase 1, Phase 25 sites📍 Duarte📍 San Francisco📍 Aurora Lyell Immunopharma, Inc. · Tests: LYL273 IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer NCT05093907Phase 1, Phase 21 site📍 Seoul BeyondBio Inc. · Tests: BEY1107, Capecitabine Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer NCT07147231Phase 1, Phase 27 sites📍 Aurora📍 Washington D.C.📍 Atlanta National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer NCT07525206Phase 388 sites📍 Goodyear📍 Springdale📍 Duarte AbbVie · Tests: Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study NCT06547203Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Cetuximab, Toripalimab, Irinotecan A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy NCT06549907n/a1 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Multi-omics testing, MRI A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168Phase 19 sites📍 San Diego📍 Denver📍 Washington D.C. Sutro Biopharma, Inc. · Tests: STRO-004, Pembrolizumab Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial NCT07722754Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: Cetuximab, Irinotecan, Bevacizumab, Sintilimab Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer NCT06102902Phase 116 sites📍 Costa Mesa📍 Irvine📍 Los Angeles National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Cetuximab, Computed Tomography Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC NCT07085169Phase 22 sites📍 Sanming📍 Shanghai Ruijin Hospital · Tests: Trifluridine/tipiracil (TAS-102) plus bevacizumab Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer NCT06654037Phase 18 sites📍 Irvine📍 Orange📍 The Bronx National Cancer Institute (NCI) · Tests: Abemaciclib, Biopsy Procedure, Biospecimen Collection, Fluorouracil, Radiologic Imaging Procedure Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment, A Phase II Study NCT07896096Phase 21 site📍 Wuhan Renmin Hospital of Wuhan University · Tests: Ivarmacitinib + Camrelizumab + Fruquintinib Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC NCT07012954Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Cetuximab (Erbitux, C225), trifluridine/tipiracil, Bevacizumab ( Avastin) Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer NCT07130903Phase 29 sites📍 Bay City📍 Clarkston📍 Detroit Barbara Ann Karmanos Cancer Institute · Tests: Fruquintinib, TheraBionic P1 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites📍 Dothan📍 Grand Rapids📍 Omaha Radiopharm Theranostics, Ltd · Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer NCT06522919Phase 22 sites📍 Meldola📍 Tricase Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Autologous Dendritic Cell (DC) Vaccine Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes NCT06949982Phase 21 site📍 Saint Petersburg Sergey Orlov, MD · Tests: experimental group x-MAP, Regorafenib (BAY 73-4506) Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease NCT06607458Phase 220 sites📍 Duarte📍 Santa Monica📍 Miami Delcath Systems Inc. · Tests: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil … A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer NCT06562543Phase 445 sites📍 Birmingham📍 Birmingham📍 Chandler Takeda · Tests: Fruquintinib Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC NCT07281716Phase 1, Phase 21 site📍 New York Dan Feng · Tests: Nadunolimab, Toripalimab A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors NCT07705334Phase 13 sites📍 Scottsdale📍 Houston📍 San Antonio SHY Therapeutics · Tests: SHY-ONC6
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy